Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CU-10101 in Healthy and Atopic Dermatitis Participants
NCT06744569Phase 1Enrolling by invitation
- Sponsor
- Cutia Therapeutics
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CU-10101 in atopic dermatitis (AD) (8 cohorts), sponsored by Cutia Therapeutics. Primary endpoints: Adverse Events assessed by CTCAE V5.0 at Day 36, Vital signs and 4 more. Started Sep 2024; status: enrolling by invitation.
02
Drugs
CU-10101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06744569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744569.